RCS - OptiBiotix Health - BBSRC Grant for WellBiome®

OptiBiotix HealthAnnouncement

22/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231122:nRSV2079Ua&default-theme=true

RNS Number : 2079U  OptiBiotix Health PLC  22 November 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

BBSRC Grant for WellBiome®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that the University of Reading has provided a grant under the
Biotechnology and Biological Science Research Council (BBSRC) to fund a
research project on WellBiome®.

 

The research project will be carried out by the University of Leeds and
provides £55,451 to assess the ability of WellBiome®, a new prebiotic and
mineral complex recently launched by OptiBiotix, to improve gut health and
wellbeing. The grant will investigate WellBiome's® impact on the gut
microbiome throughout the digestive tract and add to the existing scientific
and clinical evidence. This is anticipated to provide further substantiation
of existing health claims in international markets.

 

WellBiome® provides a scientifically formulated, patented and trademarked
solution for partners to either enter into, or extend, their product value
proposition into the gut health and health & wellness market using
functional ingredients. It has a number of existing health claims including:

 

·    Supports digestive health

 

·    Supports brain health and cognitive function

 

·    Contributes to improved bone health by aiding in the absorption of
essential minerals including magnesium, calcium and zinc

 

·    Helps sustain a healthy energy metabolism

 

·    Helps reduce systemic inflammation, which lowers the risk of type 2
diabetes and obesity

 

·    Maintains a balanced immune response, which reduces the risk of
infections and inflammation

 

·    Supports heart muscle function

 

The launch of a gut and digestive health WellBiome® product in 2023 was part
of a strategy to enhance OptiBiotix's range of product offerings and to
mitigate the seasonal variations in the sale of weight management products.
WellBiome® has received excellent reviews on Amazon with growing month on
month sales and a high number of repeat orders.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "The award of this grant to
investigate WellBiome's impact on the gut microbiome throughout its length is
another step in OptiBiotix's strategy of developing science based functional
ingredients which modify the human microbiome to improve health. Consumer
understanding and interest in the microbiome and the role of gut health in
general health and wellbeing is growing rapidly, particularly in the US, and
this is creating a market opportunity that is large and expanding. The
development of functional ingredients like WellBiome®, backed by independent
science and clinical studies and protected by a broad IP portfolio, allows
OptiBiotix and its partners to access this large and growing health and
wellbeing trend."

 

For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFESEEFEDSEIF